Burgess C, Pearce N, Thiruchelvam R, Wilkinson R, Linaker C, Woodman K, Crane J, Beasley R
Dept of Medicine, Wellington School of Medicine, New Zealand.
Eur Respir J. 1994 Mar;7(3):498-503. doi: 10.1183/09031936.94.07030498.
Inhaled fenoterol has been associated with an increased risk of death in severe asthmatics, when compared to other adrenoceptor agonists. It is plausible that fenoterol may also increase the risk of near-fatal attacks. We have conducted a case-control study to investigate this hypothesis. The cases comprised Intensive Care Unit (ICU) admissions for asthma in the Wellington region during 1977-1988. For each of these cases, two age-matched controls were selected from asthma admissions to the same hospital during the same period. For the 155 cases and 305 controls, information on prescribed drug therapy was collected from the hospital admission records. The relative risk of a near-fatal asthma attack in patients prescribed inhaled fenoterol was 2.00 (95% confidence interval (CI) 1.35-2.97). An increased risk was also observed for oral theophylline (odds ratio (OR) = 1.88; 95% CI 1.26-2.79). For the 65 cases and 104 controls who had a previous admission for asthma in the previous 12 months, information relating to the previous admission was also collected; an increased risk was once again observed for inhaled fenoterol (OR = 2.18; 95% CI 1.10-4.33) and for oral theophylline (OR = 1.18; 95% CI 0.99-3.57). No other asthma drugs showed significantly increased risks. Although the ICU admission cases had generally been prescribed more asthma drugs than the hospital admission controls, and appeared to have more severe asthma, it is possible that the findings reported here are influenced by confounding by severity. We nevertheless estimate that our findings are consistent with the hypothesis that fenoterol increases the risk of near-fatal asthma attacks, and that they complement previous findings on fatal asthma attacks.(ABSTRACT TRUNCATED AT 250 WORDS)
与其他肾上腺素能受体激动剂相比,吸入用非诺特罗与重度哮喘患者死亡风险增加有关。非诺特罗也可能增加近乎致命发作的风险,这似乎是合理的。我们进行了一项病例对照研究来调查这一假设。病例包括1977年至1988年期间惠灵顿地区因哮喘入住重症监护病房(ICU)的患者。对于每一例此类病例,从同期因哮喘入住同一家医院的患者中选取两名年龄匹配的对照。对于155例病例和305例对照,从医院入院记录中收集了有关所开药物治疗的信息。使用吸入用非诺特罗的患者发生近乎致命哮喘发作的相对风险为2.00(95%置信区间(CI)1.35 - 2.97)。口服茶碱也观察到风险增加(比值比(OR)= 1.88;95% CI 1.26 - 2.79)。对于在过去12个月内曾因哮喘入院的65例病例和104例对照,还收集了与前次入院相关的信息;吸入用非诺特罗(OR = 2.18;95% CI 1.10 - 4.33)和口服茶碱(OR = 1.18;95% CI 0.99 - 3.57)再次观察到风险增加。没有其他哮喘药物显示出风险显著增加。尽管入住ICU的病例通常比入住医院的对照开具了更多的哮喘药物,且似乎患有更严重的哮喘,但此处报告的结果可能受到严重程度混杂因素的影响。然而,我们估计我们的结果与非诺特罗增加近乎致命哮喘发作风险的假设一致,并且它们补充了先前关于致命哮喘发作的研究结果。(摘要截取自250字)